The pCR rate in IHC 2+ tumours when anti-HER2 therapy was also given was as follows: 20.3% (31/153) in HER2 amplified tumours (Groups 1, 2 and 3); 20.2% (21/104) in Group 1; 21.4% (9/42) in Group 2; and 14.3% (1/7) in Group 3. Here, ERBB2 is linked to neoplasm.